RESUMO
INTRODUCTION: If their target glycated hemoglobin (HbA1c) is not achieved after 3 months, timely treatment intensification is recommended in people with type 2 diabetes to maintain glycemic control and minimize vascular complications. We retrospectively investigated potential therapeutic inertia in the management of type 2 diabetes in multiple health care organizations across the USA. METHODS: Electronic health records were analyzed from 22 American Medical Group Association (AMGA) health care organizations. Bolus insulin-naïve patients with type 2 diabetes and HbA1c ≥ 8.0% (≥ 64 mmol/mol) at baseline were followed for 24 months to identify the frequency and average duration of therapeutic inertia (no new class of glucose-lowering medication prescribed, or not achieving their target HbA1c [< 8.0%; < 64 mmol/mol]). RESULTS: The study cohort comprised almost 28,000 patients. Therapeutic inertia was observed in ≈ 50% of patients after 6 months, and in > 10% after 24 months. Less therapeutic inertia was observed in patients receiving one or no oral antidiabetic drugs (OADs) (36% or 28%, respectively, at 6 months), while more inertia was seen following multiple OADs or basal insulin (54% of those on baseline basal insulin at 6 months). Although an observable action was recorded for 90% of patients, many (44%) had still not achieved their target HbA1c after 24 months. CONCLUSION: The results corroborate the presence of therapeutic inertia in people with type 2 diabetes, suggesting that treatment intensification guidelines are not being followed. Extensive variability in the presence of therapeutic inertia was observed both across and within organizations; investigating this further and sharing best practices across providers might help improve the quality of patient care at organizational and national levels.
People with type 2 diabetes have their glycated hemoglobin (HbA1c) level measured regularly by their care provider to check their blood sugar levels over the previous 23 months and the diabetes control achieved with their current treatment. To keep HbA1c within an individually recommended range, changes to therapies or doses may be needed, which is known as 'treatment intensification.' Despite guidelines describing this best-practice approach, 'therapeutic inertia' (not intensifying treatment when needed) is common. This therapeutic inertia may be a result of complicated or confusing guidelines, a lack of time or awareness/understanding on the part of the health care provider, or patient-specific barriers such as treatment cost or fear of side effects. Due to therapeutic inertia, patients can have poorly controlled diabetes for a long time, increasing their risk of other diabetes-related health problems or complications. This study describes widespread therapeutic inertia in the management of type 2 diabetes across the USA, suggesting that treatment intensification in patients with poor diabetes control is not taking place when needed. Diabetes-related health complications caused by poorly controlled disease over a period of time can significantly reduce quality of life. Diabetes and its complications also increase costs for the health care system due to the resulting medical costs and diabetes-related reductions in productivity. It is important to encourage early diagnosis of diabetes and appropriate and timely treatment. Investigating the variations in therapeutic inertia seen within and between health care organizations and sharing the lessons learned by the top-performing organizations may help spread best practices and improve the quality of patient care.